Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and accessible on the company's website. Rhythm focuses on rare neuroendocrine diseases with its lead drug, IMCIVREE (setmelanotide), approved for treating specific genetic obesity disorders. The presentations aim to update investors on company progress and clinical developments.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...
Auditoria.AI introduced Governed Autonomy, a new framework allowing AI agents to operate within enterprise-defined policies in finance, reducing the need for human approval on every transaction. This shift addresses governance challenges in AI deploy...
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Microchip Technology has introduced new 3.3 kV HV-D3 mSiC power modules designed to enhance solid-state transformers (SSTs) for AI hyperscale data centers. These modules integrate silicon carbide MOSFETs and Schottky diodes to improve power delivery ...
G. Willi-Food International Ltd. announced a strong first quarter for 2026, with sales increasing by 8.3% to NIS 157 million and gross profit rising 9.7% to NIS 49 million compared to the same period in 2025. Net profit grew by 3% to NIS 20.1 million...
